ESR1 and neoplasm: Using ER ChIP-seq binding in primary breast cancers from patients with different clinical outcomes (nine “Responders” vs. nine “Non-responders” and three “Metastatic tumours”), we identified ER binding sites, which were lost in non-responders (n = 14,553) and gained in non-responders (n = 1662).